No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
TEVA241220C20000
- 1.40
- +0.10+7.69%
15min DelayTrading Dec 19 09:45 ET
1.73High1.25Low
1.25Open1.30Pre Close22 Volume32.54K Open Interest20.00Strike Price3.10KTurnover93.06%IV-0.49%PremiumDec 20, 2024Expiry Date1.51Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8843Delta0.1683Gamma13.96Leverage Ratio-0.0687Theta0.0006Rho12.35Eff Leverage0.0024Vega
Intraday
- 5D
- Daily
News
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $28
Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says
U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood
Teva Pharmaceutical Indus Analyst Ratings